Genomic Profiling of Pancreatic Tumor Microenvironment for Therapeutic Targeting

Setting the Stage: The Promise of Genomic Insight

Impact of Genomic Profiling on Pancreatic Cancer Care

Genomic profiling of pancreatic ductal adenocarcinoma (PDAC) identifies driver mutations such as KRAS (>90% of cases) and DNA‑damage‑repair genes (BRCA1/2). This enables targeted therapies (e.g., PARP inhibitors, KRAS G12C inhibitors) and predicts chemotherapy response. Real‑time next‑generation sequencing of biopsies or liquid biopsies detects actionable alterations, improving outcomes for patients who receive matched therapy.

Integration of Tumor and Stromal Data

The dense desmoplastic stroma, constituting up to 80% of tumor mass, drives therapeutic resistance. Integrating tumor genomics with single‑cell RNA‑seq and spatial transcriptomics of the microenvironment reveals heterogeneous cancer‑associated fibroblast subtypes and immunosuppressive cells. This comprehensive view identifies vulnerabilities such as the CXCL12‑CXCR4 axis and hyaluronan barriers, guiding combination strategies that remodel the stroma to enhance drug delivery and immune infiltration.

Hirschfeld Oncology’s Precision‑Medicine Approach

Hirschfeld Oncology translates these insights into practice by combining standard chemotherapy (e.g., FOLFIRINOX) with targeted and immunologic agents selected from each patient’s genomic and microenvironmental profile. This multidisciplinary model aims to overcome resistance and improve survival, aligning with the latest precision‑medicine guidelines.

Understanding the Pancreatic Tumor Microenvironment (PDAC TME)

The Desmoplastic Stroma: A Physical Barrier

The PDAC tumor microenvironment (TME) is defined by a dense, desmoplastic stroma that can account for up to 80% of the tumor volume. This fibrotic tissue is rich in extracellular matrix components such as collagen, hyaluronan, and fibronectin, which create a formidable physical barrier. Hyaluronan, in particular, raises interstitial fluid pressure, compresses blood vessels, and impairs chemotherapeutic drug delivery, contributing to hypoxia and therapy resistance.

Cellular Heterogeneity in the TME

The PDAC TME exhibits remarkable cellular heterogeneity. Pancreatic stellate cells (PSCs) and cancer‑associated fibroblasts (CAFs) are key stromal constituents. Single‑cell RNA‑sequencing has revealed distinct CAF subtypes: myofibroblastic CAFs (myCAFs) that produce extracellular matrix, inflammatory CAFs (iCAFs) that secrete immunosuppressive cytokines like IL‑6 and CXCL12, and antigen‑presenting CAFs (apCAFs). Immune cells, including myeloid‑derived suppressor cells (MDSCs), tumor‑associated macrophages (TAMs), and regulatory T cells, further contribute to the complex microenvironment.

Immunosuppressive Mechanisms and the Cold Tumor Phenotype

The PDAC TME is immunologically “cold” due to active immunosuppressive mechanisms. CAFs and TAMs secrete factors that sequester and inactivate cytotoxic CD8+ T cells, while MDSCs and regulatory T cells suppress antitumor immunity. This exclusion of effector T cells, combined with the physical stromal barrier, limits the efficacy of immune checkpoint inhibitors. Recent therapeutic strategies focus on reprogramming the TME—through targeting CAF subtypes, depleting immunosuppressive myeloid cells, or modulating the extracellular matrix—to convert it into a “hot”, immune‑responsive environment.

Genomic Profiling Techniques and Clinical Integration

Whole‑Genome and Transcriptome Sequencing in the COMPASS trial

The COMPASS trial performed integrated whole‑genome and transcriptome sequencing on tumor specimens from 268 patients with advanced pancreatic ductal adenocarcinoma (PDAC). This approach identified distinct molecular subgroups: basal‑like tumors (19%) were enriched for major KRAS imbalances (KRAS^maj), correlated with pre‑existing type II diabetes, and had a median overall survival of only 6.5 months. Homologous‑recombination‑deficient (HRD) tumors (13–15%) predicted better response to mFOLFIRINOX, whereas an elevated Gustave Roussy Immune Score indicated a poor‑prognosis group with low CD8⁺ T‑cell infiltration. These findings demonstrate how comprehensive genomic and transcriptomic profiling can stratify patients into clinically relevant categories to guide therapy.

EUS‑FNA and Liquid Biopsy for Definitive Diagnosis

Endoscopic ultrasound‑guided fine‑needle aspiration (EUS‑FNA) remains the gold standard for obtaining a tissue diagnosis in suspected pancreatic cancer. It provides sufficient material for histopathological examination and next‑generation sequencing, enabling real‑time genomic assessment without surgical resection. When tissue is unavailable, liquid biopsy approaches—such as detecting KRAS mutations in circulating tumor DNA (ctDNA) from plasma—offer a non‑invasive method for early diagnosis and monitoring of disease progression.

Single‑Cell and Spatial Transcriptomics

Recent advances in single‑cell RNA sequencing (scRNA‑seq) and spatial transcriptomics have uncovered the heterogeneity of the PDAC tumor microenvironment. At least three cancer‑associated fibroblast (CAF) subtypes have been identified: myofibroblastic CAFs that reinforce the desmoplastic stroma, inflammatory CAFs that secrete immunosuppressive cytokines, and antigen‑presenting CAFs that may modulate immune responses. Spatial mapping reveals that iCAF‑rich regions correlate with higher expression of immune‑suppressive molecules such as IL‑6 and TGF‑β, and that cell‑surface targets like GPRC5A and CLDN18.2 show variable expression across and within tumors, informing logical‑gated combination strategies for precision therapy.

Barriers and Opportunities in Pancreatic Cancer Immunotherapy

Immunosuppressive TME Components

Pancreatic ductal adenocarcinoma (PDAC) is immunologically "cold," primarily due to an abundant, desmoplastic stroma that constitutes up to 80% of tumor mass. Within this stroma, immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and M2-polarized tumor-associated macrophages dominate, while cytotoxic CD8+ T cells are excluded. Cancer-associated fibroblasts (CAFs) secrete cytokines (IL‑6, TGF‑β, CXCL12) that further hinder T-cell infiltration and activation, creating a potent barrier to immunotherapy.

Limited Efficacy of Checkpoint Blockade

Single-agent immune checkpoint inhibitors (anti-PD-1/PD-L1, anti-CTLA-4) have shown negligible activity in PDAC clinical trials, with response rates below 5% in advanced disease. The dense stroma physically impedes drug penetration and fosters an environment that suppresses effector immune cells. Only the 1–3% of patients with microsatellite instability-high (MSI-H) or high tumor mutational burden (TMB-H) derive benefit from approved checkpoint inhibitors like pembrolizumab.

Combination Strategies to Overcome Resistance

Emerging opportunities focus on reprogramming the tumor microenvironment rather than simply depleting stroma. Approaches include: (1) targeting the CXCL12‑CXCR4 axis to enhance T-cell trafficking; (2) degrading hyaluronan with PEGPH20 to reduce interstitial pressure and improve drug delivery; (3) combining KRAS G12C inhibitors with immunomodulators to convert tumors to an immune-inflamed state; and (4) employing stromal-reprogramming agents (e.g., vitamin D receptor agonists, FAK inhibitors) alongside checkpoint blockade. Ongoing trials integrating vaccines, oncolytic viruses, and CAR‑T cells directed at fibroblast activation protein (FAP) show early promise in sensitizing PDAC to immunotherapy, though robust clinical validation remains needed.

Stromal Subtypes and Therapeutic Targets

Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment

The PDAC tumour microenvironment is a fibroinflammatory compartment where non‑malignant stromal cells make up the bulk of tissue volume. Single‑cell analyses define distinct cancer‑associated fibroblast (CAF) subtypes: myofibroblastic CAFs (myCAFs) express α‑SMA and deposit extracellular matrix, while inflammatory CAFs (iCAFs) secrete IL‑6 and CXCL12. The CXCL12‑CXCR4 axis excludes cytotoxic T cells, and TGF‑β signaling drives stellate cell activation and collagen production. Stromal‑directed agents aim to remodel this barrier. PEGPH20 degrades hyaluronan to reduce interstitial pressure and improve drug delivery. Focal adhesion kinase (FAK) inhibitors, such as defactinib, decrease desmoplasia and enhance immune infiltration. Vitamin D receptor (VDR) agonists like calcipotriol reprogram CAFs to a quiescent state, reducing fibrosis. These strategies target heterocellular crosstalk that sustains chemoresistance and immune evasion.

Transcription factor switching drives subtype‑specific pancreatic cancer

The orphan nuclear receptor HNF4G and pioneer factor FOXA1 form a molecular switch that drives PDAC progression. In early‑stage tumours, HNF4G dominates and maintains the classical subtype. Loss of HNF4G in advanced disease unmasks FOXA1, which establishes metastasis‑specific enhancer–promoter loops that upregulate squamous/mesenchymal genes. Consequently, overall survival is linked to HNF4G activity during primary growth and to FOXA1 activity during metastatic spread. This stage‑dependent transcription factor switching underlies subtype‑specific dynamics and highlights new therapeutic vulnerabilities.

Navigating Publication Standards: Graphical Abstracts and Authorship

Cell Reports Graphical Abstract Requirements

Cell Reports requires a graphical abstract as part of the final submission after acceptance. It must be a single, high‑resolution image file that visually summarizes the main findings. The file should be uploaded separately, typically in TIFF or PDF format. For two‑column journals, the maximum width is 17.4 cm. While exact dimensions are not specified in the provided materials, a clear, self‑explanatory layout with minimal text is recommended. Authors should always consult the journal’s specific guidelines for precise size and resolution requirements.

Authorship Change Procedures

Authorship changes—additions, removals, or reordering—require completion of the official Cell Reports authorship change form. The corresponding author must submit this form through the Editorial Manager system along with the revised manuscript. Changes are not permitted after acceptance, and unauthorized alterations may result in rejection or retraction. The form must detail the reasons for each change and confirm that all authors agree to the modification. The publisher or editor cannot mediate unresolved disputes.

Submission Workflow and Review Timelines

Manuscripts are submitted via the Editorial Manager online system. First‑time users must register for an account; returning users can log in directly. Required files include the manuscript, a cover letter, and any supplementary materials. Cell Reports is an open‑access journal; a publication fee applies upon acceptance, and authors select a Creative Commons license. For papers spanning multiple life or health sciences, authors may use Cell Press Multi‑Journal Submission for simultaneous consideration across journals. Review timelines vary but typically involve initial editorial assessment followed by peer review. Authors should monitor their submission status through the Editorial Manager dashboard.

Clinical Trials Shaping Precision Oncology for PDAC

COMPASS Trial and Molecular Subtyping

The COMPASS trial (NCT02750657) performed whole-genome and transcriptome sequencing on 268 advanced PDAC patients. Median overall survival (OS) was 9.2 months: 10.6 months with modified FOLFIRINOX (mFFX) and 8.4 months with gemcitabine-nab-paclitaxel (GnP). Basal-like RNA subtype (19% of cases) correlated with shorter OS and lower response rates. Homologous recombination deficiency (HRD) signatures (13–15% of tumors) predicted better response to platinum-based regimens. The trial also identified major KRAS allelic imbalance as an independent poor prognostic factor, with median OS of 6.3 months.

PASS-01 Trial: Comparative Chemotherapy

The PASS-01 phase II trial directly compared mFFX and GnP in metastatic PDAC. While progression-free survival was similar, OS and safety trends favored GnP. Rapid molecular profiling classified tumors into basal-like and classical subtypes; patients with basal-like tumors responded poorly overall but fared best with GnP. Real-time profiling enabled 44% of patients receiving second-line therapy to have treatment guided by study data, demonstrating a pathway toward personalized chemotherapy selection.

KRAS‑Directed Agents and Stromal Modifiers

KRAS mutations drive >90% of PDAC. Early-phase trials of KRAS G12C inhibitors (sotorasib, adagrasib) show activity, and combination trials pair these agents with stromal modifiers. Preclinical data support combining FAK inhibitors (defactinib) with immunotherapy to improve drug penetration, and PEGylated hyaluronidase (PEGPH20) to degrade hyaluronan and reduce interstitial pressure. Dual targeting strategies—such as KRAS plus CDK6, TYMS, or PTK2—are also under investigation.

Multi‑omics and Single‑Cell Perspectives on Genomic Evolution

Single‑Cell Genomic Evolution

A landmark study using single‑nucleus DNA sequencing on 137,491 nuclei from 24 pancreatic neoplasms has revealed that somatic driver alterations occur more frequently than bulk sequencing suggests, with copy‑number alterations driving most spatial heterogeneity. In tumors with canonical KRAS mutations, variable dependence on the specific genotype was uncovered, potentially predicting differential responses to KRAS‑targeted therapies. For germline heterozygous BRCA2 tumors, diverse mechanisms of wild‑type allele inactivation were identified, leading to distinct evolutionary trajectories. Inactivation of tumor‑intrinsic TGF‑β signaling was found to occur by multiple mechanisms after oncogenesis, coinciding with invasion and metastasis, indicating increasing selective pressure for this phenotype later in disease progression.

MYC‑Driven NMT Vulnerability

MYC deregulation heightens cancer cells’ reliance on N‑terminal myristoylation, rendering them susceptible to N‑myristoyltransferase (NMT) inhibition. When NMT activity is blocked, MYC‑ or MYCN‑driven cells lose myristoylation of the mitochondrial complex I assembly factor NDUFAF4. This triggers NDUFAF4 degradation, detachment of complex I from the mitochondrial membrane, and mitochondrial dysfunction, leading to selective cell death in MYC‑overexpressing tumors. In vivo, NMT inhibitors suppress or eradicate MYC‑driven tumors with minimal systemic toxicity.

GATA6 as Subtype Marker

GATA6 expression serves as a reliable surrogate biomarker to distinguish classical and basal‑like subtypes in advanced PDAC. In the COMPASS trial, RNA‑sequencing of 195 tumor biopsies classified 80% as classical and 20% as basal‑like, with GATA6 levels strongly correlating with subtypes. Patients with classical tumors had a significantly higher overall response rate (33%) to chemotherapy than those with basal‑like tumors (10%). This distinction is clinically important, as the basal‑like subtype is associated with worse treatment outcomes and overall survival.

Biomarkers and Molecular Subtypes Guiding Therapy

GATA6 and Transcriptional Subtypes

GATA6 expression levels define two distinct molecular subtypes in pancreatic cancer: the classical (GATA6-high) and the aggressive basal-like (GATA6-low) subtype. Patients with classical tumors show superior overall survival and better response to modified FOLFIRINOX, whereas basal-like tumors derive greater benefit from gemcitabine plus nab-paclitaxel. GATA6 status thus serves both as a prognostic and predictive biomarker, guiding first-line therapy selection.

HRD, BRCA, and KRAS as Actionable Biomarkers

Homologous recombination deficiency (HRD), often driven by BRCA1/2 mutations, is identified in 13–15% of PDAC cases. HRD-positive tumors respond well to platinum-based chemotherapy and PARP inhibitors like olaparib. KRAS mutations occur in over 90% of PDAC, with G12D being most common. Major KRAS allelic imbalance is linked to worse survival and lower response rates. KRAS wild-type tumors often harbor alternative drivers such as BRAF, ERBB2, or NTRK fusions, which are targetable with existing agents.

Prognostic Stromal Proteins

Integrated transcriptomic analyses have identified FN1 (fibronectin), MSLN (mesothelin), and VCAN (versican) as hub genes whose high expression correlates with poorer overall survival. These extracellular matrix proteins are overexpressed in PDAC stroma and contribute to tumor aggressiveness, stromal remodeling, and immune evasion, highlighting their potential as prognostic biomarkers and therapeutic targets.

Future Directions: Integrated Multi‑omics and TME Normalization

Future Directions: Integrated Multi‑omics and TME Normalization

Combination of Stromal Remodelers with Immunotherapy Targeting the desmoplastic stroma alone has shown limited success, but combining stromal remodelers with immunotherapy holds promise. For example, inhibiting the CXCL12‑CXCR4 axis with plerixafor enhances T‑cell infiltration and sensitizes tumors to checkpoint blockade. Focal adhesion kinase (FAK) inhibitors such as defactinib, when paired with anti‑PD‑L1, reduce desmoplasia and increase immune activity. Vitamin D receptor agonists like calcipotriol can reprogram cancer‑associated fibroblasts, improving drug delivery and immune cell access.

Nanomedicine and Biomaterial‑Based Drug Delivery Engineered biomaterials offer precise control over drug release within the tumor microenvironment. Nanoparticles functionalized with ligands targeting fibroblast activation protein (FAP) or overexpressed surface antigens (e.g., TROP2, CLDN18.2) can concentrate chemotherapeutics and immunomodulators in the stroma. TME‑responsive carriers that degrade under low pH or high matrix metalloproteinase activity enable spatiotemporally controlled delivery, overcoming the physical barrier of dense extracellular matrix.

Microbiome and Metabolic Modulation The gut microbiome influences systemic immunity and therapy response in pancreatic cancer. Diversity of specific bacterial species (Saccharopolyspora, Pseudoxanthomonas) is associated with long‑term survival. Microbial metabolites like trimethylamine N‑oxide (TMAO) and 3‑indoleacetic acid (3‑IAA) can boost anti‑tumor immunity or sensitize cells to chemotherapy. Metabolic targeting, such as glutamine antagonists combined with PD‑1 inhibitors, improves CD8+ T‑cell function in preclinical models.

These integrated strategies, guided by multi‑omics profiling, aim to normalize the tumor microenvironment rather than ablate it, transforming immune‑cold pancreatic tumors into responsive ones.

Looking Ahead: Transforming Pancreatic Cancer Care with Genomic Insight

Genomic profiling has become the cornerstone of precision oncology for pancreatic ductal adenocarcinoma (PDAC). Comprehensive next‑generation sequencing of tumor tissue, either from surgical specimens or endoscopic ultrasound‑guided fine‑needle aspiration biopsies, consistently identifies the core driver mutations in KRAS, TP53, CDKN2A, and SMAD4. KRAS itself is mutated in more than 90% of cases, and recent work — including the COMPASS trial — has shown that specific KRAS variants and allelic imbalances carry distinct prognostic and therapeutic implications. Beyond these classic drivers, sequencing panels now routinely detect actionable alterations in DNA‑damage repair genes such as BRCA1, BRCA2, and ATM, as well as microsatellite instability, NTRK fusions, and rare kinase fusions. The Know Your Tumor program has demonstrated that patients whose treatment plans are guided by such molecular findings can experience survival benefits exceeding one year compared with unmatched therapy. International guidelines now recommend germline and somatic genomic testing for every patient with advanced disease, and the same principles are increasingly being applied in the resectable setting to inform neoadjuvant and adjuvant strategies.

The promise of genetic insights extends beyond tumor cells themselves. The pancreatic tumor microenvironment (TME) — a dense, fibrotic, and immunosuppressive ecosystem that can make up 80% of the tumor mass — is now recognized as a co‑conspirator that must be addressed therapeutically. Single‑cell RNA sequencing and spatial transcriptomics have mapped the heterogeneous populations of cancer‑associated fibroblasts (CAFs), myeloid‑derived suppressor cells, tumor‑associated macrophages, and regulatory T cells that populate this stroma. The iCAF subtype secretes IL‑6, CXCL12, and other cytokines that shield the tumor from immune attack, while myCAFs deposit collagen and hyaluronan that physically obstruct drug delivery. These stromal interactions are not passive: tumor‑mutant KRAS drives the secretion of GM‑CSF and other factors that actively remodel the TME toward an immune‑excluded, pro‑tumorigenic state.

Accordingly, the most promising therapeutic strategies now involve synergistic targeting of both the malignant epithelium and its supportive niche. Direct KRAS inhibitors — such as sotorasib and adagrasib for the G12C variant — are entering PDAC trials, and their combination with agents that reprogram the stroma is showing preclinical synergy. For example, blocking the CXCL12‑CXCR4 axis with plerixafor can improve T‑cell infiltration, while FAK inhibitors like defactinib reduce desmoplasia and sensitize tumors to checkpoint blockade. Degrading hyaluronic acid with PEGPH20 or activating the vitamin D receptor to quiesce CAFs are additional strategies that normalize the microenvironment. On the immune front, CD40 agonists re‑educate macrophages, and anti‑CSF1R agents push TAMs from a pro‑tumor M2 phenotype toward an anti‑tumor M1 state. The key insight is that modulation, not ablation, of stromal components is required — indiscriminate depletion can paradoxically accelerate disease.

Hirschfeld Oncology’s vision for integrated, patient‑centric care aligns closely with these advances. Their multidisciplinary model combines standard chemotherapy backbones — such as FOLFIRINOX or gemcitabine/nab‑paclitaxel — with an ever‑expanding arsenal of targeted and immunologic agents selected on the basis of each patient’s unique genomic and microenvironmental profile. By performing comprehensive molecular profiling at diagnosis, the practice aims to identify actionable mutations, predict chemoresistance, and match patients to the most appropriate clinical trials. This approach acknowledges that pancreatic cancer is not a single disease but a collection of molecular subtypes — classical versus basal‑like, for instance — that respond differently to therapy. Real‑time monitoring via circulating tumor DNA and extracellular vesicles allows the team to adapt treatment as resistance emerges.

Looking ahead, the convergence of KRAS‑directed therapies, stromal reprogramming, and immune reactivation holds the potential to transform PDAC from a uniformly lethal malignancy into a manageable chronic condition. The path forward requires not only novel drug combinations but also the systematic integration of genomic data into every stage of care — from early detection and risk stratification through recurrence management. Hirschfeld Oncology’s commitment to this science‑driven, personalized framework offers a blueprint for how the next generation of pancreatic cancer treatment should be delivered. By treating the whole biology of the tumor — its cells, its stroma, and its immune milieu — clinicians can finally begin to break the barrier that has kept survival rates stagnant for decades.